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Abstract
Introduction: People living with HIV (PLHIV) on antiretroviral therapy (ART), with sustained undetectable viral load (sUVL) and no
history of sexually transmitted infections for at least six months, are considered to have a low risk of HIV transmission (LRT). We
aimed to characterize, in a representative sample of French PLHIV, the sexual behaviour of LRT PLHIV compared with non-LRT
PLHIV.
Methods: The cross-sectional ANRS-VESPA2 survey was conducted on adult PLHIV attending French hospitals in 2011. The LRT
PLHIV group included participants with sUVL and no sexually transmitted infection for at least 12 months. Socio-behavioural and
medical data were collected. Chi-square tests helped compare sexual risk indicators between LRT and non-LRT PLHIV. The
survey’s retrospective nature allowed us to perform complementary category-based analyses of LRT PLHIV according to whether
they had sUVL for at least 18, 24 or 36 months in three socio-epidemiological groups: men who have sex with men (MSM), other
men and women.
Results: Analysis included 2638 PLHIV diagnosed 12 months with available viral load data. The proportion of LRT PLHIV varied
from 58% (]12 months sUVL) to 38% (]36 months sUVL). Irrespective of sUVL duration, we found the following: 1) LRT men
(MSM and other men) were more likely to report having no sexual partner than their non-LRT counterparts. Among men having
sexual partners in the previous 12 months, no significant difference was seen between LRT and non-LRT men in the number of
sexual partners. LRT women were less likely to report having more than one sexual partner than non-LRT women; 2) LRT MSM
were more likely to report being in sexually inactive couples than their non-LRT counterparts; 3) among sexually active
participants, no difference was observed between LRT and non-LRT PLHIV concerning condom use with their serodiscordant
steady partner or with their most recent casual sexual partners.
Conclusions: LRT PLHIV with sUVL ]12 months did not report more sexual risk behaviours than their non-LRT counterparts.
Because the same result was obtained for those having a sUVL ]36 months, the hypothesis of increased sexual risk behaviour
over time in PLHIV meeting non-transmission biomedical criteria is not supported.
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Introduction
Antiretroviral therapies (ART) are now part of combination
HIV prevention strategies, as their efficacy in decreasing
blood plasma viral load (VL) has led to a dramatic reduction
in HIV-1 sexual transmission among heterosexual serodiscor-
dant couples [14]. In 2008, the Swiss Federal Commission
for HIV/AIDS stated that HIV-positive heterosexual individuals
on effective ART  individuals having an undetectable plasma
VL for at least six months with no sexually transmitted
infection (STI) during the same period  can be considered
sexually non-infectious [5]. This statement has led to
considerable debate about possible sexual risk disinhibition
or risk compensation in this population [610], offsetting the
benefits of current biomedical HIV prevention strategies.
This issue is particularly important since the number of
new HIV diagnoses continues to grow in the most vulnerable
populations, especially men who have sex with men (MSM).
This is the case in France where a 14% increase was observed
between 2011 and 2013 in this population [11].
Systematic reviews or meta-analyses of the association
between ART, risk perception and sexual behaviour show
no or short-term increases in sexual risk behaviour among
people receiving ART [1215]. Meta-analysis by Crepaz et al.
demonstrated no higher rates of condomless sex between
people living with HIV (PLHIV) on ART with a detectable VL
and with undetectable VL (UVL). However there was a high
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prevalence of condomless sex in persons  with known or
unknown HIV status  who believed that being on ART or
having an UVL protects against HIV transmission or who were
less concerned about engaging in unsafe sex because of ART
availability. A review of recent findings also supported the
relationship between treatment-related optimistic beliefs
and HIV transmission risk [16]. Recent results from the Swiss
HIV Cohort Study showed increased condomless sex with
stable partners, after 2008, among MSM and heterosexual
ART-treated PLHIV with a UVL. It was suggested that this
increase was possibly the consequence of PLHIV believing
that HIV treatment was a sufficient prevention strategy [17].
More recently, a cross-sectional study among a nationally
representative sample of US PLHIV engaged in care showed
that the majority did not engage in sexual risk behaviour
and that half of those who did had a detectable VL during
the previous 12 months [18]. The heterogeneity of results
published in the literature reflects the diversity of the study
designs they come from (longitudinal studies, cohorts, cross-
sectional surveys), the diversity of the studied populations
(heterosexual couples, MSM, drug users) and potential cross-
cultural differences. However results from behavioural cohorts
or from representative samples of PLHIV are scarce. We used
data collected during the ANRS-VESPA2 survey to analyze, for
the first time, the evolution over time of sexual risk behaviour
in three distinct socio-epidemiological groups: MSM, women
and other men, according to the biomedical criterion of HIV
transmission risk.
The cross-sectional ANRS-VESPA2 survey was performed
among a nationally representative sample of adult PLHIV living
in France in 2011 to provide information on various aspects
of their conditions, including socio-demographic, epidemiolo-
gical and health status data as well as HIV medical care
characteristics. More than 93% of patients were receiving
ART, and among them approximately 57% had a CD4 cell
count 500 cells/mm3, whereas 88.5% had a controlled VL.
The present study aimed to analyze, in this representative
sample, the sexual risk behaviour of ART-treated PLHIV
meeting the biomedical criteria for low HIV transmission risk
(LRT), defined in the present study as having an undetectable
VL for at least 12months and no STI in the previous 12months,
compared with their non-LRT counterparts. The goal was
to determine whether less infectious individuals engaged
more in sexual risk behaviour. Despite its cross-sectional
nature, the ANRS-VESPA2 design allowed us to retrospectively
collect participants’ medical data from the French electronic
database Nadis†, in turn enabling us to carry out comple-
mentary analyses by categories of LRT PLHIV according
to different durations of UVL. Our working hypothesis was
that successful and sustained VL control does not translate
into increased sexual risk behaviour in PLHIV.
Methods
Design and setting
The national cross-sectional ANRS-VESPA2 survey took place
from April 2011 to January 2012 in 68 HIV care services in
French hospitals. A representative sample of 3022 patients
was included in the survey after patients provided written
informed consent. Patients were drawn randomly from among
9098 eligible patients (i.e. 18 years old, HIV-diagnosed
longer than six months, living in France for more than six
months and attending participating outpatient services at
the time of the study). Independent trained interviewers
administered a face-to-face questionnaire to collect data
about patients’ socio-demographic characteristics, different
aspects of their lives with HIV, their social trajectory during the
course of the disease and their sexual behaviours. Medical
staff completed a questionnaire about patients’ health status,
HIV history, co-morbidities and all prescribed treatments.
Data were weighted and calibrated to be representative of
the entire population of PLHIV followed-up on in French hos-
pitals in 2011. To this end, individual weights were computed
accounting for both the unequal probability of random
selection and the heterogeneous rates of non-participation
between PLHIV subgroups. A comprehensive description
of the survey methodology can be found elsewhere [19].
The ANRS-VESPA2 study was approved by the Commission
Nationale de l’Informatique et des Liberte´s, the French data
protection authority (approval number DR-2010-368).
Participants
The analysis included 2638 PLHIVof the 3022 patients enrolled
in the VESPA2 survey, HIV-diagnosed 12 months and with
available data on VL status (i.e. detectable VL at the time of
the survey, or with known duration of sustained UVL (sUVL)
for those who had achieved it). We retrospectively defined
the duration of sUVL for each participant using medical data.
Three socio-epidemiological groups were created based on
participants’ response to the question ‘‘Would you define
yourself as heterosexual/bisexual/homosexual/transgender?’’
as follows: 1) MSM (self-identified as homosexual, bisexual
or heterosexual men reporting at least one male sexual
partner); 2) other men (self-identified as heterosexual report-
ing only female partners); and 3) women (irrespective of
sexual identity or behaviour).
No significant differences were observed between excluded
(n384) and included study sample participants (n2638)
regarding socio-epidemiological group, CD4 cell count and VL
at most recent assessment and disease clinical stage. Partici-
pants were defined as LRT if they were receiving ART, had
a sUVL ]12 months and reported no STI in the previous
12 months (n1419). This 12 month criterion was chosen
to define LRT, instead of the six months used in the Swiss
statement, based on the STI item in our study questionnaire.
Variables
Duration of sustained undetectable VL
The retrospective nature of the ANRS-VESPA2 survey helped
us define different sUVL groups according to sUVL duration:
]12, ]18, ]24 or ]36 months, which in turn enabled us
to carry out complementary analyses to observe whether
outcomes of participants in a more restrictive definition of
sUVL (e.g. sUVL ]36 months) were different from those in a
less restrictive definition of sUVL (e.g. sUVL ]12 months).
Sexual risk behaviour outcome
Sexual risk behaviour was evaluated using the following three
variables as risk proxies: 1) total number of sexual partners in
the previous 12 months (categorized into no partner, 1 to 20
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and 20 partners for MSM; no partner, 1 or 1 for other
men and women); 2) condomless vaginal/anal intercourse with
a serodiscordant steady partner in the previous 12 months;
and 3) condomless vaginal/anal sex during the most recent
encounter with a non-HIV-positive (i.e. HIV-negative or un-
known status) casual partner. Participants reporting having a
steady partner for ]12 months were considered to be in a
stable couple. Categorizing the number of sexual partners in
the previous 12 months was used to obtain a homogeneous
distribution of the sample size in each socio-epidemiological
group considered. The range of partner numbers differed
greatly between MSM, other men and women (median [CI]
6 [2 to 20], 2 [1 to 4] and 2 [1 to 3], respectively).
Condomless sex
For participants having a serodiscordant steady partner,
condomless sex (‘‘yes’’) was defined as inconsistently or never
using condoms (versus ‘‘no,’’ i.e., always using condoms)
during vaginal/anal intercourse in the previous 12 months.
When considering the most recent encounter with a non-
HIV-positive (i.e. HIV-negative or unknown status) casual
partner, condomless sex was defined as no condom use
(‘‘yes’’ versus ‘‘no’’) during vaginal/anal intercourse.
Statistical analysis
Three sexual risk behaviour proxies were considered: 1) the
number of sexual partners for each participant; 2) condom
use during anal or vaginal intercourse within serodiscordant
couples in the previous 12 months; and 3) condom use
during anal or vaginal intercourse with the most recent non-
HIV-positive casual partner. Sexual risk behaviour was
evaluated by comparing these risk proxies between LRT and
non-LRT patients for the three socio-epidemiological groups:
MSM, other men and women. Chi-square tests were used
for all comparisons, with a significance threshold of 5%, and
a 10% threshold to reflect marginal significance. The same
analyses were performed using different durations of sUVL
among the LRT PLHIV: ]18, ]24 and ]36 months. In
addition, a sensitivity analysis was performed after removing
the criterion ‘‘absence of STIs in the previous 12 months’’
for PLHIV at ‘‘low risk of transmission,’’ since STIs were self-
reported, with no corresponding medical data. Another ana-
lysis compared the LRT PLHIV in each socio-epidemiological
subgroup with their non-LRT counterpart PLHIV on treatment.
The latter were either virally suppressed and had experi-
enced an STI in the previous 12 months or were not virally
suppressed for the full time period considered. All analyses
were performed on weighted and calibrated data. Stata/SE
12.1 for Windows (StataCorp LP, College Station, TX, USA)
software was used for the analyses.
Results
Among the 2638 PLHIV included in the study, 1163 were
MSM (44.1%), 828 women (31.4%) and 647 other men
(24.5%). Table 1 shows the main patient characteristics.
Women were younger than MSM and other men with,
respectively, a median (interquartile range, or IQR) age of 44
(36 to 50) years versus 49 (42 to 55) and 50 (45 to 56). They
were also less likely to have an educational level higher than
secondary school (34.8% versus 60.6% and 38.8%, respec-
tively). Overall, median time since HIV diagnosis and on ART
was 10 years and 7 years, respectively. Over 50% of the
study sample had CD4 cell counts 500 cells/mm3 at their
most recent assessment. Most patients were receiving ART
at the time of the survey (n2498, 93.6%).
Overall, 58.1% (n1419) of the study sample was con-
sidered to have a low risk of HIV transmission (LRT) for a sUVL
of 12 months. Restricting the definition of sUVL among LRT
PLHIV reduced this proportion as follows: 52.2% (n1254)
for sUVL]18 months, 46.8% (n1103) for ]24 months and
38.2% (n880) for ]36 months (Figure 1).
Patients considered not to have an LRT were either
untreated (6.4%), were receiving ART and had a detectable
VL (19.4%), were on ART and had sUVL but for a duration
less than each of the four specific durations under considera-
tion (12.5%, 18.8%, 24.7% and 33.8% for B12, B18, B24 and
B36 months of sUVL, respectively) or were on ART with sUVL
for a duration greater than each of the four specific durations
under consideration but reported at least one STI in the
Table 1. Main characteristics of VESPA2 survey participants, diagnosed with HIV 12 months, with data on their viral load
(n2638)
MSMa
n1163
n (%) median (IQR)
Women
n828
n (%) median (IQR)
Other mena
n647
n (%) median (IQR) p
Age 49 (42 to 55) 44 (36 to 50) 50 (45 to 56) B103
Education  secondary school or above 60.6 34.8 38.8 B103
Time since HIV diagnosis (years) 14.3 (6.6 to 20.3) 10.8 (6.3 to 18.9) 13.3 (7.3 to 20.6) 0.002
Time on ART (years) 10.3 (3.5 to 14) 7.6 (4.1 to 12.2) 9.7 (4.4 to 13.8) B103
CD4 cell count at most recent assessment
B200 cells/mm3 52 (3.5) 42 (4.9) 49 (6.1) 0.008
200 to 350 149 (12.6) 125 (13.2) 98 (19.4)
350 to 500 243 (22.1) 124 (24.5) 195 (23.8)
500 715 (61.8) 353 (57.4) 484 (50.7)
aMSM, men who have sex with men; other men, men who only have sex with women. IQR, interquartile ratio; ART, antiretroviral therapy.
Suzan-Monti M et al. Journal of the International AIDS Society 2016, 19:20095
http://www.jiasociety.org/index.php/jias/article/view/20095 | http://dx.doi.org/10.7448/IAS.19.1.20095
3
previous year (3.6%, 3.2%, 2.7% and 2.2% for ]12, ]18,
]24 and ]36 months of sUVL, respectively).
The proportion of LRT versus non-LRT participants in the
three groups considered (i.e. MSM, women and other men)
according to time is detailed in Figure 2.
Table 2 compares the total number of sexual partners in
the previous 12 months between LRT and non-LRT PLHIV
within each socio-epidemiological group according to the
different definitions of sUVL. LRT MSM with sUVL for ]12 or
]18 months were significantly more likely to report no
Figure 1. Distribution of participants among the study sample according to antiretroviral therapy treatment, virological status and according
to minimum time (months) defining sustained undetectable viral load for participants with low HIV transmission risk (n2638).
Figure 2. Distribution of participants among the study sample (n2638) according to whether they had low HIV transmission risk (LRT) or not,
within each socio-epidemiological group, and the minimum time (months) defining sustained undetectable viral load for LRT participants.
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partners than their non-LRT counterparts (p0.01 and
p0.007, respectively), but these differences were no longer
significant for MSM with an LRT for the ]24- or ]36-month
definitions of sUVL. Among MSM with sexual partners in the
previous 12 months, no significant difference in the number of
sexual partners could be observed between LRT and non-LRT
participants. Irrespective of the definition of sUVL considered,
LRT women were less likely to have more than one partner
than their non-LRT counterparts. Other LRT men with sUVL
defined as ]36 months were significantly more likely to have
oneormorepartners than their non-LRTcounterparts (p0.02).
Among other men with sexual partners in the previous
12 months, no significant difference could be observed in
the number of sexual partners between LRT and non-LRT
participants.
In the study sample, 1038 (39.3%) patients reported being
in stable serodiscordant couples. Table 3 compares condom-
less sex for LRT and non-LRT PLHIV with a serodiscordant
steady partner, during vaginal/anal intercourse among sexu-
ally active couples, and sexual abstinence within couples, for
the previous 12 months.
In sexually active couples among each socio-epidemiological
group, no significant differences were observed between LRT
and non-LRT PLHIV regarding condom use with a serodiscordant
steady partner, irrespective of the different definitions of sUVL for
LRTparticipants.The exceptionwas LRTMSMwith sUVL for]36
months who showed a trend towards significantly less unpro-
tected intercourse than their non-LRT counterparts (p0.07).
LRTMSMwith sUVL for]18months weremore likely to engage
in sexual abstinence than their non-LRT counterparts (p0.05),
and a trend towards significance was observed when considering
LRT MSM with sUVL for ]24 or ]36 months (p0.08 and
0.06, respectively). No significant difference was observed for
this between LRT and non-LRT women and other men.
Less than one-third of PLHIV of the study sample (n746)
reported having a non-HIV-positive casual partner in the
previous 12 months. Among these, the only trend observed
was towards a lower proportion of other LRT men with
sUVL for ]24 months reporting condom use during their
most recent sexual encounter with a non-HIV-positive casual
partner when compared with their non-LRT counterparts
(p0.09, Table 4).
The robustness of the results was confirmed after
adjustment for age, educational level, income and time since
diagnosis (data not shown). Moreover the results were
confirmed by two sensitivity analyses. The first was performed
after removing the criterion ‘‘absence of STIs in the previous
12 months’’ for PLHIV defined as being at low risk of
transmission, since STIs were self-reported, with no corre-
sponding medical data. The second compared the LRT PLHIV
in each socio-epidemiological subgroup with their non-LRT
counterpart PLHIV on treatment. The latter were either virally
suppressed and had experienced an STI in the previous
12 months or were not virally suppressed for the full time
period considered. Although some differences were observed
in the second analysis (demonstrating the impact on our
results of PLHIV  untreated or treated  with a detectable
VL), these two analyses provided the same results: PLHIV
meeting the biomedical criterion of HIV risk transmission did
not report more sexual risk behaviours than their non-LRT
counterparts.
Discussion
Our results highlighted that PLHIV at LRT did not report
more sexual risk behaviours than PLHW with higher risk of
transmission. Indeed, LRT PLHIV in serodiscordant stable
couples were more likely to be sexually abstinent, and both
LRT MSM and women reported fewer sexual partners than
their non-LRT counterparts. Moreover, rates of condom use
within serodiscordant stable couples and during the most
recent sexual encounter with a serodiscordant casual partner
were, overall, similar between LRT and non-LRT groups. In line
Table 2. Total number of sexual partners in the previous 12 months according to the biomedical risk of HIV transmission (n2638)
Minimum time with undetectable viral load
12 months 18 months 24 months 36 months
Group
Number of
partnersa
LRT
(%)b
Non-
LRT (%)b
p a vs. (bc)
c
p b vs. c
d
LRT
(%)b
Non-
LRT (%)b
p a vs. (bc)
c
p b vs. c
d
LRT
(%)b
Non-
LRT (%)b
p a vs. (bc)
c
p b vs. c
d
LRT
(%)b
Non-
LRT (%)b
p a vs. (bc)
c
p b vs. c
d
MSM
(n1163)
None(a)
1 to 20(b)
20(c)
24
62
14
17
63
20
0.01
nse
25
61
14
18
63
19
0.007
ns
24
62
14
19
63
18
ns
ns
22
63
15
20
62
18
ns
ns
Women
(n828)
None(a)
1(b)
1(c)
38
57
5
38
51
11
ns
0.01
37
58
5
39
51
10
ns
0.02
38
57
5
38
52
10
ns
0.05
40
54
6
38
52
10
ns
ns
Other men
(n647)
None(a)
1(b)
1(c)
26
56
18
30
52
18
ns
ns
25
57
18
30
51
19
ns
ns
24
56
20
31
52
17
ns
ns
21
58
21
32
51
17
0.02
ns
aNumber of partners: total number of sexual partners in the previous 12 months; b%, weighted percentage of patients; cindividuals having no
partner in the previous 12 months (a) were compared with those who had at least one sexual partner (bc); dcomputed on individuals
reporting at least one sexual partner in the previous 12 months; ens, not significant, p0.10; LRT, low risk of HIV transmission.
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Table 4. Condomless sex with the most recent non-HIV-positive casual partner (n746)
Minimum time since undetectable viral load
12 months 18 months 24 months 36 months
Group
Variable:
Condomless sexa LRT (%)b
Non-
LRT (%)b p LRT (%)b
Non-
LRT (%)b p LRT (%)b
Non-
LRT (%)b p LRT (%)b
Non-
LRT (%)b p
MSM (n526) No 93 90 93 90 92 91 92 91
Yes 7 10 nsc 7 10 nsc 8 9 nsc 8 9 nsc
Women (n89) No 89 89 89 89 92 83 90 84
Yes 11 11 ns 11 16 ns 8 17 ns 10 16 ns
Other men (n131) No 84 94 82 94 82 94 85 91
Yes 16 6 ns 18 6 0.10 18 6 0.09 15 9 ns
Total (n746) No 91 90 90 90 90 90 90 90
Yes 9 10 ns 10 10 ns 10 10 ns 10 10 ns
acondomless sex, unprotected anal or vaginal intercourse; b%, weighted percentage of patients; cns, not significant, p0.10; LRT, low risk of HIV
transmission; MSM, men who have sex with men.
Table 3. Sexual practices in serodiscordant couples in the previous 12 months (n1038)
Minimum time since undetectable viral load
12 months 18 months 24 months 36 months
Group Variable
LRT
(%)a
Non-
LRT (%)a
p(ab) vs. c
b
pa vs b
LRT
(%)a
Non-
LRT (%)a
p(ab) vs. c
b
pa vs b
LRT
(%)a
Non-
LRT (%)a
p (ab) vs c
b
p a vs b
LRT
(%)a
Non-
LRT (%)a
p(ab) vs. c
b
p a vs b
MSM
(n382)
Sexually inactive
couplesc(c)
25 17 0.10 26 16 0.05 26 17 0.08 27 18 0.06
Condomless
sexd
No(b) 63 65 62 66 63 65 64 63
Yes(a) 12 18 nse 12 18 ns 11 18 ns 9 19 0.07
Women
(n338)
Sexually inactive
couples(c)
15 9 ns 15 10 ns 15 10 ns 15 11 ns
Condomless sex
No(b) 52 60 51 61 51 60 55 55
Yes(a) 33 31 ns 34 29 ns 34 30 ns 30 34 ns
Other men
(n318)
Sexually inactive
couples(c)
15 11 ns 14 12 ns 14 13 ns 12 14 ns
Condomless sex
No(b) 68 69 69 67 69 67 70 66
Yes(a) 17 20 ns 17 21 ns 17 20 ns 18 20 ns
Total
(n1038)
Sexually inactive
couples(c)
18 12 0.03 18 13 0.07 18 14 ns 18 14 ns
Condomless sex
No(b) 61 65 60 64 60 64 63 62
Yes(a) 21 23 ns 22 23 ns 22 22 ns 19 24 ns
a%, weighted percentage of patients; bsexually active individuals (ab) were compared to sexually inactive individuals (c); csexually inactive
couples, no sexual intercourse with any type of partner; dcondomless sex, unprotected anal or vaginal intercourse with a serodiscordant steady
partner in the previous 12 months; ens, not significant, p0.10; LRT, low risk of HIV transmission.
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with results reported from a nationally representative sample
of US PLHIV engaged in care [18], a majority of participants
did not engage in condomless sex, either in serodiscordant
couples or with the most recent non-HIV-positive casual
partner. Virally suppressed MSM were significantly less likely
to engage in sexual risk behaviour than their non-virally
suppressed counterparts. Due to their cross-sectional design,
neither the American study nor ours was able to evaluate
changes in sexual risk behaviour before and after ART
initiation, or VL suppression. However, both demonstrated
that PLHIV with sUVL did not engage in sexual risk behaviour.
The present results are also in line with those reported in
several systematic reviews or meta-analyses on the associa-
tion between ART and sexual behaviour. Although based on
studies conducted in 1996 to 2003, before conclusive evidence
that ART reduces HIV transmission risk, a 2004 meta-analysis
comparing PLHIV on ART with a detectable VL to their
counterparts with an UVL [12] highlighted that the rates of
condomless sex were not higher in the latter group. The study
showed that in general people (irrespective of serostatus)
who believed that ART reduced HIV transmission were more
likely to engage in condomless sex. Subsequent reviews in
the developing world such as those by Kennedy et al. [13],
Venkatesh et al. [14] and Kaye et al. [15] have reported either
a transient increase or no increase in sexual risk behaviours
following ART initiation. Furthermore, a recent review of
studies conducted in developed countries provides additional
support to the present study, as it underlined that PLHIV who
were aware of their HIV-positive status and those on ART
had decreased sexual risk behaviour [20].
It is well known that risk behaviour changes according to
HIV disease stage [21]. Few studies have examined long-term
risk behaviour changes in those living with HIV and on ART.
Results from one such study, the Swiss HIV prospective cohort,
showed an association between suppressive ART and in-
creased unsafe sex among MSM and heterosexual women
[17]. This result came two years after the publication of the
Swiss statement when contrary results, similar to those of
the present study, were published for the same Swiss cohort
[22,23]. The present study’s results are concordant with those
from a sexual risk behaviour survey in 2007 among partici-
pants in a US prospective observational cohort ongoing since
1993, the HIV Outpatient Study, which reported no difference
in condomless anal intercourse (despite it being very frequent)
with partners of unknown or HIV-negative status among vire-
mic or virologically suppressed MSM followed-up on in eight
outpatient HIV clinics [24].
The 2013 French experts’ recommendations for PLHIV
medical care advocated for ART initiation regardless of CD4
cell count, based on individual and public health benefits
resulting from ART effectiveness [25]. In this context, under-
standing the relationship between viral suppression and sexual
risk behaviour is particularly important. Results from a French
cross-sectional community-based survey conducted in 2010
showed that 57% of participating PLHIV knew about the
Swiss statement and 65% of the latter reported no change in
condom use with HIV-negative partners. In that survey,
awareness of the Swiss statement was significantly associated
with having a UVL [26]. As the VESPA2 survey was conducted
in 2011, it might be plausible that at least a portion of
participants were aware of new biomedical HIV prevention
approaches, however without this having any measurable
impact on their sexual behaviour.
Our study has several limitations. First, the cross-sectional
design of the VESPA2 survey did not allow us to evaluate
sexual risk compensation over time, since this model con-
cerns changes in risk perceptions and behaviour over time
and requires knowledge of participants’ sexual behaviour
before receiving ART or before achieving sustained UVL.
Retrospective questions to investigate behaviour changes
over time might have induced substantial recall bias, since
participants in the study sample had been living with HIV for a
rather long period of time. However such questions were not
asked. Median duration time since diagnosis was 10.8 years
and median time on ART was 7.6 years. Second, we lacked
data about patients’ perception of transmission risk, aware-
ness of the Swiss statement and perceptions of ART and
of undetectable VL as prevention tools. This prevented
any analysis about possible differences in transmission risk
perception between having an undetectable versus detectable
VL, or between having a recent STI versus no STI. Moreover,
without this information we cannot exclude the possibility that
participants on ART (i.e. 93% of those in participating in
VESPA2) believed they were at low risk of transmission thanks
to their treatment, but did not understand that their risk
also depended on achieving sUVL and absence of STI.
Third, sexual behaviours were assessed through face-to-face
interviews, so underreporting socially unacceptable beha-
viours and inaccuracy of self-reported information cannot be
completely excluded. Since both the Swiss study and our own
assessed sexual behaviours through face-to-face interviews,
discrepancy in results might be explained by the differences
in both surveys’ designs (prospective cohort versus cross-
sectional study) and in the national health care contexts where
they took place (Switzerland versus France).
Despite its cross-sectional nature, our study is the first to
be conducted among a nationally representative sample of
PLHIV  including MSM, other men and women  that
analyzes sexual risk behaviour according to the biomedical
criterion of HIV transmission risk. The first wave of the VESPA
survey was conducted in 2003. Despite a higher proportion of
PLHIV with an UVL in 2011 with respect to 2003, the overall
frequency of unsafe sex with serodiscordant steady partners,
albeit showing some variation, remained comparable over
time for MSM, other men and women [2729]. This suggests
that, at least in the French context, increased ART efficiency
does not translate into increased sexual risk behaviour.
Risk compensation is currently a major issue regarding
current and future users of new biomedical HIV prevention
strategies [10,30,31]. The concern surrounding MSM is even
greater mainly because HIV prevalence and incidence are
still increasing in this population in most countries [32,33],
including France, where MSM represented 43% of new HIV
diagnoses in 2013 [11]. These two concerns underline the
importance of including this topic in secondary HIV preven-
tion interventions, in order to prevent any relapse into unsafe
behaviours that might occur over time.
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Conclusions
Our results do not support the hypothesis of increased sexual
risk behaviour among PLHIV presenting non-transmission
biomedical characteristics in France. Indeed, some risk in-
dicators suggested the opposite tendency. Positive long-term
impacts of biomedical HIV prevention approaches, including
ART, need to be accompanied by behavioural interventions,
especially for high-risk individuals. Studies linking behavioural
and clinical data are also necessary to assess the extent to
which patients’ awareness of their VL might affect their sexual
behaviour.
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